Zevra Therapeutics, Inc. (ZVRA)
| Market Cap | 200.47M |
| Revenue (ttm) | 10.46M |
| Net Income (ttm) | -41.54M |
| Shares Out | 34.49M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | 263.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,350 |
| Open | 5.38 |
| Previous Close | 5.49 |
| Day's Range | 5.30 - 5.64 |
| 52-Week Range | 4.00 - 6.92 |
| Beta | 2.16 |
| Analysts | n/a |
| Price Target | 18.87 (+243.09%) |
| Earnings Date | May 11, 2023 |
About ZVRA
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disor... [Read more]
Financial Performance
In 2022, ZVRA's revenue was $10.46 million, a decrease of -63.50% compared to the previous year's $28.65 million. Losses were -$41.54 million, -33.95% less than in 2021.
Financial StatementsNews
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced t...
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
New Patent Issued Covering Serdexmethylphenidate (SDX), the Sole Active Pharmaceutical Ingredient in KP1077, Zevra's Product Candidate for the Treatment of Idiopathic Hypersomnia (IH)
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
Urges Shareholders to Vote "FOR" All Zevra Director Nominees on the WHITE Proxy Card
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 7, 2023, 8:30 a.m. ET
Zevra Therapeutics to Present at 35th Annual Roth Conference
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today annou...
Zevra Therapeutics Begins Trading as ZVRA
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting today, March 1, 2023
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its prelimi...
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that...
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC)
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that...
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community
KemPharm Announces Corporate Name Change to Zevra Therapeutics
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community
KemPharm Enhances Senior Management Team
Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy
KemPharm Issues Letter to Shareholders
CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare c...
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia (IH) KemPharm advancing multicenter Phase 2 clinical t...
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A.
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial...
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and severi...
KemPharm Announces Appointment of Christopher Posner as New Independent Director
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022
KemPharm to Report Third Quarter 2022 Financial Results
CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of ...
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of ...
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
SDX administered at single doses of 80 mg and 200 mg was well-tolerated
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercia...